Our story
XEMPERIA SA, is a science-driven startup founded in 2023 by Prof. Curzio Rüegg, Dr. Sarah Cattin and Dr. Tuto Rossi, as spin-off from the University of Fribourg, Switzerland. Built on over 25 years of pioneering translational cancer research and biomarker discovery expertise.
The Team
XEMPERIA, is driven by a passionate, multidisciplinary team with complementary expertise spanning cancer biology, oncology diagnostics, biostatistics, artificial intelligence, legal affairs, and business strategy. United by a shared mission to revolutionize breast cancer care, we harness cutting-edge science and innovation to transform early detection and monitoring.
MD, trained in internal medicine, immunology, cell and molecular biology (Basel, Zürich, San Francisco). Chair of Pathology, UNIFR, Friburg.
PhD in Medical Sciences, UNIFR (Fribourg). Specialist in cancer biomarkers and molecular biology Extensive experience in translational studies and cell analytics.
Lawyer with extensive experience in creating and supporting start-ups. Law and notary firm, Bellinzona.
MD-PhD, PD, Clinical oncologist, Head Breast Center, Dept. of Oncology CHUV-UNIL, Lausanne, Switzerland.
PhD in Immuno-Oncology, with extensive experience in translational medicine, clinical studies, and regulatory affairs. PMP and GCP certified.
PhD in Medical Sciences & Diagnostics and DNA nanotechnology. Research Associate, UNIFR, Fribourg.
The SAB
XEMPERIA is supported by a Scientific Advisors Board (SAB) consisting of leaders in cancer biology, cancer biomarkers, translational and clinical oncology
Director of the Tumor Biology Institute, Universitäts Klinikum Eppendorf, Hamburg, Germany. Pioneer of the liquid biopsy field.
MD, Clinical oncologist, Director of the Interception medico-scientific program, Institut Gustave Roussy, (IGFR), Paris, France.
PhD, Translational Breast Cancer, Research. Katholieke Universiteit Leuven (KLU), Leuven, Belgium.
PhD, Biologist Translational Bioinformatics and Statistics. Emeritus head of Bioinformatics Core Facility (BCF) UNIL-SIB, Lausanne, Switzerland.
MD, Clinical oncologist. Member of the International Breast Cancer Study Group (IBCSG). Emeritus head breast cancer clinic and research, IOSI, Bellinzona, Switzerland.
PhD, Translational Breast Cancer, Research. Katholieke Universiteit Leuven (KLU), Leuven, Belgium